RxSight (NASDAQ:RXST) Given New $9.00 Price Target at Wells Fargo & Company

RxSight (NASDAQ:RXST) had its target price trimmed by Wells Fargo & Company from $11.00 to $9.00 in a report published on Thursday,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other research firms have also recently issued reports on RXST. Wolfe Research raised shares of RxSight to an “outperform” rating in a report on Friday, January 30th. Stifel Nicolaus cut their price target on shares of RxSight from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Monday, March 9th. William Blair began coverage on shares of RxSight in a report on Friday, January 30th. They set a “market perform” rating on the stock. Piper Sandler dropped their target price on shares of RxSight from $11.00 to $10.00 and set a “neutral” rating on the stock in a report on Thursday, February 26th. Finally, Needham & Company LLC dropped their target price on shares of RxSight from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $9.44.

RxSight Price Performance

RXST opened at $5.80 on Thursday. The stock has a market capitalization of $240.12 million, a PE ratio of -5.13 and a beta of 1.24. The firm’s fifty day moving average price is $7.11 and its 200 day moving average price is $8.93. RxSight has a 12-month low of $5.30 and a 12-month high of $16.74.

Institutional Trading of RxSight

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new stake in shares of RxSight during the second quarter worth $28,000. Summit Securities Group LLC bought a new position in shares of RxSight during the first quarter worth about $30,000. Larson Financial Group LLC grew its position in shares of RxSight by 110.5% during the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock worth $36,000 after acquiring an additional 2,089 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of RxSight by 440.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock worth $39,000 after acquiring an additional 3,063 shares during the last quarter. Finally, CWM LLC grew its position in shares of RxSight by 211.1% during the fourth quarter. CWM LLC now owns 3,826 shares of the company’s stock worth $40,000 after acquiring an additional 2,596 shares during the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight News Roundup

Here are the key news stories impacting RxSight this week:

• Positive Sentiment: Q1 revenue beat estimates — RxSight reported $30.89M in revenue vs. analyst estimates of $29.75M, a modest upside that suggests resilience in top-line demand. Zacks Q1 Revenue Beat
• Positive Sentiment: Company reiterated its full-year sales outlook in its press release, which can be read as management maintaining confidence in FY26 execution despite the quarter’s challenges. GlobeNewswire Press Release
• Neutral Sentiment: Needham cut its price target from $13 to $11 but kept a “buy” rating, signaling continued analyst conviction in upside longer term even as near-term assumptions were trimmed. Benzinga – Needham The Fly – Needham
• Negative Sentiment: Wells Fargo lowered its price target from $11 to $9 and moved to an “equal weight” rating — a clear near-term negative signal that likely pressured the stock. Benzinga – Wells Fargo
• Negative Sentiment: Q1 earnings missed estimates: RxSight reported a ($0.19) EPS vs. a ($0.12) consensus and a larger loss than a year ago, highlighting margin pressure and raising short-term profitability concerns. MarketBeat Earnings
• Negative Sentiment: FY26 revenue guidance was issued at $120M–$135M versus a consensus near $129.1M; the range includes outcomes below street expectations, which may temper near-term upside. Company Guidance
• Negative Sentiment: Brokerage consensus has shifted toward caution — the stock received an average “Reduce” rating from brokerages in a recent survey, increasing selling pressure. AmericanBankingNews

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.